Abbott Laboratories (ABT) Short-Term Debt repayments (2017 - 2021)
Abbott Laboratories recorded quarterly Short-Term Debt repayments of $195.0 million in Q4 2021, down 59.29% quarter-over-quarter from $479.0 million in Q1 2017.
Abbott Laboratories' Short-Term Debt repayments history runs 2 years deep, the most recent figure standing at $195.0 million for Q4 2021.
- In Q4 2021, Short-Term Debt repayments changed N/A year-over-year to $195.0 million; the TTM figure through Dec 2021 stood at $195.0 million (changed N/A YoY), while the FY2021 annual figure was $195.0 million, changed N/A from the prior year.
- Short-Term Debt repayments came in at $195.0 million for Q4 2021 at Abbott Laboratories, down from $479.0 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $479.0 million in Q1 2017 to a low of $195.0 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 259.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 195.00 Mn |
| Dec 31, 2021 | 195.00 Mn |
| Mar 31, 2017 | 479.00 Mn |
| Mar 31, 2017 | 479.00 Mn |